Literature DB >> 12893986

Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

Deanna L Kroetz1, Christiane Pauli-Magnus, Laura M Hodges, Conrad C Huang, Michiko Kawamoto, Susan J Johns, Doug Stryke, Thomas E Ferrin, Joseph DeYoung, Travis Taylor, Elaine J Carlson, Ira Herskowitz, Kathleen M Giacomini, Andrew G Clark.   

Abstract

OBJECTIVES: There is increasing evidence that polymorphism of the ABCB1 (MDR1) gene contributes to interindividual variability in bioavailability and tissue distribution of P-glycoprotein substrates. The aim of the present study was to (1) identify and describe novel variants in the ABCB1 gene, (2) understand the extent of variation in ABCB1 at the population level, (3) analyze how variation in ABCB1 is structured in haplotypes, and (4) functionally characterize the effect of the most common amino acid change in P-glycoprotein. METHODS AND
RESULTS: Forty-eight variant sites, including 30 novel variants and 13 coding for amino acid changes, were identified in a collection of 247 ethnically diverse DNA samples. These variants comprised 64 statistically inferred haplotypes, 33 of which accounted for 92% of chromosomes analyzed. The two most common haplotypes, ABCB1*1 and ABCB1*13, differed at six sites (three intronic, two synonymous, and one non-synonymous) and were present in 36% of all chromosomes. Significant population substructure was detected at both the nucleotide and haplotype level. Linkage disequilibrium was significant across the entire ABCB1 gene, especially between the variant sites found in ABCB1*13, and recombination was inferred. The Ala893Ser change found in the common ABCB1*13 haplotype did not affect P-glycoprotein function.
CONCLUSION: This study represents a comprehensive analysis of ABCB1 nucleotide diversity and haplotype structure in different populations and illustrates the importance of haplotype considerations in characterizing the functional consequences of ABCB1 polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893986     DOI: 10.1097/00008571-200308000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  98 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Finding haplotype tagging SNPs by use of principal components analysis.

Authors:  Zhen Lin; Russ B Altman
Journal:  Am J Hum Genet       Date:  2004-09-23       Impact factor: 11.025

3.  Inference from the relationships between linkage disequilibrium and allele frequency distributions of 240 candidate SNPs in 109 drug-related genes in four Asian populations.

Authors:  Pei-Chieng Cha; Ryo Yamada; Akihiro Sekine; Yusuke Nakamura; Chong-Lek Koh
Journal:  J Hum Genet       Date:  2004-09-11       Impact factor: 3.172

4.  Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.

Authors:  Tuija Tapaninen; Pertti J Neuvonen; Mikko Niemi
Journal:  Eur J Clin Pharmacol       Date:  2010-05-23       Impact factor: 2.953

Review 5.  Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.

Authors:  Megan M Donohue; David L Tirschwell
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

Review 6.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Authors:  Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

Review 7.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 8.  Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.

Authors:  Magnus Ingelman-Sundberg; Cristina Rodriguez-Antona
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 9.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

10.  Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.

Authors:  Diego Alberto C Cusinato; Riccardo Lacchini; Elen A Romao; Miguel Moysés-Neto; Eduardo B Coelho
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.